Table 4.
Comparison of laboratory examination between AE– and AE+ groups*
| Laboratory examinations | BCOS (n = 118) | AE– (n = 50) | AE+ (n = 68) | P-value |
|---|---|---|---|---|
| Blood routine |
|
|
|
|
|
WBC ( × 109/L)
|
6.99 (5.47–9.02) |
6.99 (5.72–8.71) |
6.87 (5.44–9.02) |
0.365 |
|
HB (g/L)
|
131 (117–140) |
135 (116–143) |
131 (119–139) |
0.492 |
|
PLT ( × 109/L)
|
237 (181–294) |
245 (177–318) |
237 (182–278) |
0.618 |
|
Neutrophils ( × 109/L)
|
4.90 (3.90–7.10) |
4.90 (4.10–7.10) |
4.90 (3.40–6.80) |
0.341 |
|
Lymphocytes ( × 109/L)
|
1.19 (0.89–1.46) |
1.14 (0.80–1.46) |
1.22 (1.00–1.44) |
0.508 |
|
Eosinophils ( × 109/L)
|
0.15 (0.06–0.25) |
0.16 (0.05–0.29) |
0.14 (0.07–0.23) |
0.715 |
|
Eosinophils ≥0.3 × 109/L, n (%)
|
26 (22.0) |
12 (24.0) |
14 (20.6) |
0.659 |
|
LNR
|
0.25 (0.17–0.32) |
0.23 (0.17–0.29) |
0.15 (0.18–0.38) |
0.042 |
| Inflammatory markers |
|
|
|
|
|
CRP (mg/L)
|
7.50 (3.50–16.90) |
4.80 (3.10–11.70) |
9.90 (4.30–20.80) |
0.006 |
|
ESR (mm/h)
|
22 (7–45) |
13 (7–29) |
25 (11–53) |
0.032 |
|
PCT (mg/L)
|
0.10 (0.05–0.11) |
0.10 (0.05–0.12) |
0.07 (0.05–0.10) |
0.201 |
| Hepatic and renal function |
|
|
|
|
|
ALB (g/L)
|
35.00 (32.30–37.70) |
35.80 (31.10–37.70) |
35.00 (32.50–37.70) |
0.851 |
|
GLO (g/L)
|
27.20 (24.60–31.10) |
27.10 (24.60–30.70) |
27.80 (24.90–31.20) |
0.537 |
|
Creatinine (μmol/L)
|
65.30 (56.40–76.60) |
65.40 (58.20–78.70) |
65.10 (56.10–75.80) |
0.750 |
|
BUN (mmol/L)
|
4.80 (3.90–6.20) |
5.10 (3.70–6.10) |
4.80 (4.10–6.20) |
0.963 |
| Blood gas analysis |
|
|
|
|
|
PH
|
7.40 (7.38–7.43) |
7.40 (7.38–7.44) |
7.40 (7.37–7.42) |
0.254 |
|
Pco2 (mmHg)
|
48 (43–56) |
49 (43–54) |
47 (43–58) |
0.991 |
|
Po2 (mmHg)
|
70 (58–82) |
69 (60–80) |
71 (57–83) |
0.585 |
|
Sao2
|
94 (90–96) |
94 (91–96) |
94 (89–96) |
0.844 |
| Immunoglobulin |
|
|
|
|
|
IgM (g/L)
|
0.81 (0.65–1.11) |
0.88 (0.55–1.11) |
0.81 (0.68–1.11) |
0.983 |
|
IgA (g/L)
|
2.02 (1.66–2.95) |
2.65 (1.74–4.16) |
1.93 (1.58–2.94) |
0.182 |
|
IgG (g/L)
|
12.20 (10.80–14.10) |
12.10 (9.11–14.10) |
12.70 (11.20–14.90) |
0.667 |
|
IgE (g/L)
|
183 (71–403) |
172 (65–213) |
190 (108–403) |
0.259 |
| Sputum culture, n (%) |
|
|
|
|
|
Positive sputum culture
|
40 (43.5) |
16 (38.1) |
24 (48.0) |
0.03 |
|
Candida albicans
|
7 (7.6) |
4 (9.5) |
3 (6.0) |
0.525 |
|
Pseudomonas aeruginosa
|
17 (18.5) |
4 (9.5) |
13 (26.0) |
0.043) |
| Gram negative bacilli | 4 (4.3) | 2 (4.8) | 2 (4.0) | 0.858 |
AE – acute exacerbation, AE+ – acute exacerbation occurred during the follow-up period, AE– – no acute exacerbation occurred during the follow-up period, ALB – albumin, BCOS – bronchiectasis-chronic obstructive pulmonary disease overlap syndrome, BUN – blood urea nitrogen, CRP – C-reactive protein, ESR – erythrocyte sedimentation rate, GLO – globulin, HB – haemoglobin, IgA – immunoglobulin A, IgE – immunoglobulin E, IgG – immunoglobulin G, IgM – immunoglobulin M, IQR – interquartile range, LNR – lymphocyte to neutrophil ratio, MD – median, Pco2 – partial pressure of carbon dioxide, PCT – procalcitonin, PH – the potential of hydrogen, PLT – platelets, Po2 – partial pressure of oxygen, Sao2 – arterial oxygen saturation, WBC – white blood cell
*Presented as MD (IQR) unless specified otherwise.